Based on the Ironwood Pharmaceuticals Inc stock forecast from 5 analysts, the average analyst target price for Ironwood Pharmaceuticals Inc is USD 11.43 over the next 12 months. Ironwood Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ironwood Pharmaceuticals Inc is Neutral, which is based on 6 positive signals and 7 negative signals. At the last closing, Ironwood Pharmaceuticals Inc’s stock price was USD 4.19. Ironwood Pharmaceuticals Inc’s stock price has changed by +0.96% over the past week, -2.56% over the past month and -55.89% over the last year.
No recent analyst target price found for Ironwood Pharmaceuticals Inc
No recent average analyst rating found for Ironwood Pharmaceuticals Inc
Company Overview Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Read Less
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with con...Read More
Frequently Asked Questions About Ironwood Pharmaceuticals Inc (IRWD) Stock
Based on ratings from 5 analysts Ironwood Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 5 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on IRWD's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for IRWD is USD 11.43 over the next 12 months. The maximum analyst target price is USD 23 while the minimum anlayst target price is USD 4.
IRWD stock's Price/Earning ratio is 52.38.
Our analysis grades IRWD stock's Price / Earning ratio at F. This means that IRWD stock's Price/Earning ratio is above 63% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this IRWD may be a overvalued for its sector.
The last closing price of IRWD's stock was USD 4.19.
The most recent market capitalization for IRWD is USD 0.67B.
Based on targets from 5 analysts, the average taret price for IRWD is projected at USD 11.43 over the next 12 months.
This means that IRWD's stock price may go up by +172.76% over the next 12 months.
We can't find any ETFs which contains Ironwood Pharmaceuticals Inc's stock.
As per our most recent records Ironwood Pharmaceuticals Inc has 267 Employees.
Ironwood Pharmaceuticals Inc's registered address is 100 Summer Street, Boston, MA, United States, 02110.
You can get more information about it from Ironwood Pharmaceuticals Inc's website at https://www.ironwoodpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Ironwood Pharmaceuticals Inc (IRWD) Stock
Based on ratings from 5 analysts Ironwood Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 5 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on IRWD's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for IRWD is USD 11.43 over the next 12 months. The maximum analyst target price is USD 23 while the minimum anlayst target price is USD 4.
IRWD stock's Price/Earning ratio is 52.38.
Our analysis grades IRWD stock's Price / Earning ratio at F. This means that IRWD stock's Price/Earning ratio is above 63% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this IRWD may be a overvalued for its sector.
The last closing price of IRWD's stock was USD 4.19.
The most recent market capitalization for IRWD is USD 0.67B.
Based on targets from 5 analysts, the average taret price for IRWD is projected at USD 11.43 over the next 12 months.
This means that IRWD's stock price may go up by +172.76% over the next 12 months.
We can't find any ETFs which contains Ironwood Pharmaceuticals Inc's stock.
As per our most recent records Ironwood Pharmaceuticals Inc has 267 Employees.
Ironwood Pharmaceuticals Inc's registered address is 100 Summer Street, Boston, MA, United States, 02110.
You can get more information about it from Ironwood Pharmaceuticals Inc's website at https://www.ironwoodpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IRWD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
